Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions: Tuberculosis, Multidrug-Resistant; Tuberculosis; Tuberculosis, Pulmonary; Mycobacterium Infections; Bacterial Infections; Gram-Positive Bacterial Infections Interventions: Drug: Bedaquiline 100 MG; Drug: Delamanid 50 MG Oral Tablet; Drug: Clofazimine Pill; Drug: Linezolid Pill; Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors: Médecins Sans Frontières, France; Partners in Health; Harvard Medical School; Epicentre; Institute of Tropical Medicine, Belgium; Socios En Salud, Peru; Interactive Research and Development Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Belgium Health | France Health | Multidrug Resistance | Peru Health | Research | Tuberculosis